Peterson E M, Hoshiko M, Markoff B A, Lauermann M W, de la Maza L M
Department of Pathology, University of California, Irvine 92717.
Infect Immun. 1990 Apr;58(4):938-43. doi: 10.1128/iai.58.4.938-943.1990.
Sera from seven patients from whom a C. trachomatis serovar L2 strain was isolated were tested in vitro for their ability to neutralize the infectivity of this organism. In one patient an inguinal lymph node was culture positive, whereas the remaining six patients had positive rectal biopsies. Sera from four of the patients, including the patient with the lymph node isolate, failed to neutralize serovar L2(434). In addition, the homologous strain recovered from the inguinal lymph node was available and was resistant to neutralization by the homologous sera. However, the same sera effectively neutralized a trachoma serovar, E(Bour). All four sera had inclusion immunofluorescent-antibody titers to C. trachomatis serovar L2 of 2,048 to 16,384 and microimmunofluorescent-antibody titers to the lymphogranuloma venereum biovar were equal or higher in all cases than to the 12 serovars of the trachoma biovar. The three remaining sera, while neutralizing the infectivity of the L2 strains tested, neutralized serovar E to a greater extent. These sera had the same inclusion immunofluorescent antibody titers as the sera that failed to neutralize serovar L2. To see whether this difference in the sensitivity of the biovars toward neutralization could be characterized, sera were obtained from mice immunized with different doses of both serovars L2 and E. Sera obtained from mice immunized with serovar E were able to effectively neutralize the homologous strain. In contrast, neutralization of the immunizing strain, L2(UCI-20), was not seen with sera obtained on days 7, 14, and 21 after immunization from animals receiving 8 x 10(5) and 8 x 10(4) inclusion-forming units of L2(UCI-20); however, these same sera neutralized serovar E. However, with a higher immunizing dose of L2 (10(7) IFUs), both E and L2 were neutralized with sera obtained 7 and 14 days after immunization. Therefore, the relative resistance to neutralization by serovar L2 compared with that of serovar E in the mouse model was inoculum dependent.
从7名分离出沙眼衣原体L2血清型菌株的患者身上采集血清,在体外检测其中和该病原体感染性的能力。1名患者的腹股沟淋巴结培养呈阳性,其余6名患者的直肠活检呈阳性。包括淋巴结分离株患者在内的4名患者的血清未能中和L2(434)血清型。此外,从腹股沟淋巴结分离出的同源菌株对同源血清的中和具有抗性。然而,相同的血清能有效中和沙眼血清型E(Bour)。所有4份血清对沙眼衣原体L2血清型的包涵体免疫荧光抗体滴度为2048至16384,对性病性淋巴肉芽肿生物变种的微量免疫荧光抗体滴度在所有情况下均等于或高于对沙眼生物变种的12种血清型。其余3份血清在中和所检测的L2菌株感染性的同时,对E血清型的中和作用更强。这些血清的包涵体免疫荧光抗体滴度与未能中和L2血清型的血清相同。为了确定生物变种对中和敏感性的这种差异是否可以被表征,从用不同剂量的L2和E血清型免疫的小鼠身上获取血清。用E血清型免疫的小鼠获得的血清能够有效中和同源菌株。相比之下,在接种8×10⁵和8×10⁴个L2(UCI - 20)包涵体形成单位的动物免疫后第7、14和21天获得的血清中,未观察到对免疫菌株L2(UCI - 20)的中和作用;然而,这些相同的血清能中和E血清型。然而,用更高剂量的L2(10⁷ IFUs)免疫后,在免疫后第7天和第14天获得的血清能中和E和L2。因此,在小鼠模型中,与E血清型相比,L2血清型对中和的相对抗性取决于接种量。